Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9556MR)

This product GTTS-WQ9556MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9556MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7520MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ7322MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ4168MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ11436MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ4694MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ6686MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ13979MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ11546MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGA031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW